#Canada #Toronto #Apotex #Health Canada #CLOBIVIS™

Apotex Unveils CLOBIVIS™: A Significant Step for Canadian Ophthalmology

On March 25, 2026, Apotex Inc., the largest global pharmaceutical company based in Canada, proudly announced the approval of its new ophthalmic treatment, CLOBIVIS™ (clobetasol propionate ophthalmic suspension, 0.05%). This innovative product has been approved by Health Canada specifically for treating postoperative inflammation and pain associated with cataract surgeries, signifying a considerable extension of Apotex's ophthalmology portfolio.

CLOBIVIS™ has been developed using advanced nanoparticle technology to ensure a consistent and effective ophthalmic suspension. This method not only enhances the drug's efficacy but also represents a technological leap in providing high-quality health solutions to patients. Apotex has emphasized its commitment to offering innovative treatments, aiming to improve patient access to essential medications.

Martin Arès, President of Apotex Canada and Rest of World, stressed the importance of this launch, stating, "As a Force for Health, our mission at Apotex is to guarantee that patients have access to groundbreaking treatments. The authorization of CLOBIVIS™ is a crucial milestone in our efforts to expand the availability of ophthalmic medicines for Canadians. This product embodies our Journey of Health Strategy, which is aimed at broadening access to novel therapies."

In the healthcare sector, it is vital for professionals to refer to the complete Product Monograph for comprehensive information regarding any warnings, precautions, adverse reactions, and monitoring requirements that may be necessary for patient safety. Such detailed documentation plays an essential role in ensuring that healthcare providers can deliver the best possible care following the introduction of new medical treatments.

About Apotex

Founded in Canada, Apotex is globally recognized for its commitment to increasing access to affordable and innovative medications and health products. The company offers a diverse portfolio that includes generic, biosimilar, and branded pharmaceuticals, along with consumer health products. Apotex is headquartered in Toronto and operates regional offices throughout various countries, including the United States, Mexico, and India, solidifying its status as a preferred health partner across the Americas for pharmaceutical licensing and product acquisitions. Apotex remains dedicated to improving the health and wellbeing of millions worldwide — ensuring that cutting-edge treatments like CLOBIVIS™ reach the patients who need them most.

This new approval from Health Canada is not only a testament to Apotex's innovative capabilities but also a clear demonstration of their strategic efforts to broaden the spectrum of treatment options available to patients recovering from surgical procedures, ultimately driving forward their mission of enhancing health outcomes across Canada.